Nuveen’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.5M Buy
250,036
+33,798
+16% +$1.56M ﹤0.01% 1323
2025
Q4
$9.69M Sell
216,238
-8,051
-4% -$338K ﹤0.01% 1572
2025
Q3
$9.01M Sell
224,289
-4,278
-2% -$151K ﹤0.01% 1613
2025
Q2
$7.15M Buy
+228,567
New +$7.46M ﹤0.01% 1707
2024
Q2
Sell
-42,473
Closed -$1.83M 3425
2024
Q1
$1.83M Buy
42,473
+2,109
+5% +$97K ﹤0.01% 2443
2023
Q4
$1.86M Sell
40,364
-1,331
-3% -$47K ﹤0.01% 2444
2023
Q3
$1.42M Buy
41,695
+1,496
+4% +$56K ﹤0.01% 2432
2023
Q2
$1.55M Sell
40,199
-13,108
-25% -$521K ﹤0.01% 2469
2023
Q1
$1.91M Buy
53,307
+2,027
+4% +$74.9K ﹤0.01% 2352
2022
Q4
$2.02M Buy
51,280
+920
+2% +$33.5K ﹤0.01% 2383
2022
Q3
$1.82M Buy
50,360
+6,049
+14% +$217K ﹤0.01% 2443
2022
Q2
$1.35M Sell
44,311
-5,486
-11% -$166K ﹤0.01% 2647
2022
Q1
$1.57M Buy
49,797
+7,913
+19% +$237K ﹤0.01% 2623
2021
Q4
$1.31M Buy
41,884
+12,586
+43% +$376K ﹤0.01% 2758
2021
Q3
$448K Sell
29,298
-24,156
-45% -$420K ﹤0.01% 3186
2021
Q2
$995K Buy
53,454
+35,811
+203% +$660K ﹤0.01% 3009
2021
Q1
$316K Buy
17,643
+5,043
+40% +$85.5K ﹤0.01% 3165
2020
Q4
$194K Buy
+12,600
New +$147K ﹤0.01% 3201

Other funds holding XENE

Nuveen's XENE Position: Q1 2026 in Review

Nuveen increased its Xenon Pharmaceuticals (XENE) stake by 16% in Q1 2026, buying an estimated $1.56M and bringing the position to 250,036 shares worth $14.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1323.

Nuveen first reported a position in XENE in Q4 2020 and has held it in 18 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Nuveen held 250,036 shares of Xenon Pharmaceuticals worth $14.5M as of Q1 2026.
  • Nuveen bought 33,798 Xenon Pharmaceuticals shares in Q1 2026, an estimated $1.56M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1323 holding.
  • Nuveen first reported a position in Xenon Pharmaceuticals in Q4 2020 and has held it in 18 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.